SEC Form 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b). \Box

FORM 4

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					or Se	ction 30(h)	of the I	nvestment	Con	npany Act	of 1940							
1. Name and Address of Reporting Person [*] Edwards Martin					2. Issuer Name and Ticker or Trading Symbol Verona Pharma plc [VRNA]							(Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
												X Directo	Director		10% Ow	ner		
(Last) (First) (Middle) 3 MORE LONDON RIVERSIDE					3. Date of Earliest Transaction (Month/Day/Year) 04/28/2023								Officer below)	(give title		Other (s below)	pecify	
					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. li	6. Individual or Joint/Group Filing (Check Applicable					
(Street)								0			,	Line	e)					
LONDO	N X	0	SE1 2RE												•	ting Person	20	
													Form filed by More than One Reporting Person					
(City)	(5	State)	(Zip)															
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
Date				2. Transac Date (Month/Da	Execution Date,			Code (Instr.				Beneficia Owned Fe	Form ly (D) o		Direct I Indirect E str. 4)	7. Nature of Indirect Beneficial Ownership		
				Code				v	Amount	(A) o (D)	r Price	Reported Transacti (Instr. 3 a	on(s)			Instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	Code (Inst				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivativ Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securitie Beneficia Owned Following Reported Transacti	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				Code	v	(A)		Date Exercisabl		Expiration Date	Title	Amount o Number o Shares		(Instr. 4)	.511(5)			
Share Options (Right to Buy)	\$2.67 ⁽¹⁾	04/28/2023		A		96,000 ⁽¹⁾		(2)	0	4/27/2033	Ordinary Shares	96,000 ⁽¹) \$0	96,000)(1)	D		
Explanatio	n of Respons	ses:																

1. The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

2. The option vests and becomes exercisable as to 25% on each of July 28, 2023, October 28, 2023, January 28, 2024 and April 28, 2024.

<u>/s/ Claire Poll, Attorney-in-fact</u> 04/28/2023

for Martin Edwards

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.